News

Preparing for Lazard's Earnings Release: What to Expect

Preparing for Lazard's Earnings Release: What to Expect

Preparing for Lazard's Earnings Release

Lazard (NYSE: LAZ) is gearing up for its next quarterly earnings announcement. Investors are eagerly anticipating insights that could shape their strategies for the upcoming quarter.

What Analysts Are Predicting

Analysts project that Lazard will report an earnings per share (EPS) of $0.43. The prevailing hopes within the market point towards exceeding expectations and offering positive guidance, which can significantly influence stock prices.

Past Earnings Overview

Last quarter, Lazard surpassed EPS estimates by $0.13, resulting in a notable 0.44% spike in share prices the following day. This type of performance typically excites investors, setting a precedent for future earnings reports.

Evaluating Stock Performance

As of October 21, Lazard shares were trading at $50.92. Throughout the past 52 weeks, the stock has experienced a downturn of 2.32%. This downward trend leaves long-term investors feeling a bit anxious ahead of the upcoming earnings release.

Analyst Sentiments on Lazard

Gaining insight into market sentiment is crucial for investors, and recent reports highlight various perspectives on Lazard. The current consensus among five analyst ratings is Neutral, with an average one-year price target of $60.4, suggesting a promising upside potential of 18.62%.

Peer Comparisons

To provide context, let’s explore how Lazard measures up to its peers like PJT Partners, Moelis, and Etoro Group. This analysis reveals performance expectations across the sector.

  • PJT Partners holds a Neutral rating, with an impressive one-year price target of $192.5, indicating a massive upside of 278.04%.
  • Moelis has received an Outperform rating, with an anticipated price target of $81.0, reflecting a solid upside of 59.07%.
  • Etoro Group, rated as a Buy, sees a price target of $65.17, which translates to a potential 27.99% upside.

Examining Peer Dynamics

The peer analysis sheds light on the financial health and market positioning of key players in the industry. Here are the findings:

Company Consensus Revenue Growth Gross Profit Return on Equity
Lazard Neutral 16.23% $288.75M 8.10%
PJT Partners Neutral 12.97% $130.05M 20.81%
Moelis Outperform 38.09% $113.27M 8.30%
Etoro Group Buy 13.11% $209.72M 2.73%

Key Insights

Lazard ranks in the middle concerning revenue growth relative to its peers, while its gross profit figures show strength. However, it falls short in return on equity compared to the others. Overall, Lazard's performance offers mixed results when assessed by these benchmarks.

Understanding Lazard’s Legacy

Founded in 1848, Lazard Inc has established a legacy in the financial advisory realm, focusing on mergers, acquisitions, and restructuring, alongside its asset management endeavors. The company caters primarily to institutional clients and has a diverse revenue stream geographically, with a notable presence across more than 20 countries and a workforce of over 3,000 employees.

In-Depth Financial Analysis of Lazard

Lazard's market capitalization is currently below industry norms, which raises questions about its growth prospects compared to its rivals. Nevertheless, the most recent reported revenue growth rate of 16.23% marks a significant achievement, even as it trails behind sector averages.

Net Margin Insights: Lazard's net margin stands at 6.74%, indicating room for improvement in profitability and cost management.

Return on Equity Analysis: On a positive note, Lazard's return on equity is recorded at 8.1%, showcasing effective management practices and utilization of capital.

Return on Assets: The company's return on assets is also commendable at 1.25%, reflecting efficient asset management.

Debt Metrics: Caution is advised regarding Lazard’s debt-to-equity ratio of 2.98, illustrating increased reliance on debt financing and potential financial risk.

Frequently Asked Questions

What is the expected EPS for Lazard's upcoming quarter?

Analysts anticipate an EPS of $0.43 for the upcoming earnings report.

How has Lazard performed historically in its earnings reports?

In the prior quarter, Lazard exceeded EPS expectations by $0.13, prompting a positive share price reaction.

What are analysts saying about Lazard's stock?

The consensus rating from analysts for Lazard is Neutral, with a potential upside target suggesting growth opportunities.

How does Lazard compare to its peers?

Lazard shows mixed performance relative to peers, ranking in the middle for revenue growth while leading in gross profit.

What is the significance of earnings guidance for Lazard?

Earnings guidance is crucial as it helps investors gauge future performance and informs their investment decisions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

D-Wave Investors Face Pressure Ahead of December 15

Updated Category News Views 3

Investors Eye December 15 Deadline Nothing like a looming deadline to stir up some anxiety among investors, and that's exactly what's going down at D-Wave Quantum Inc. right now. We're talking about the class action lawsuit spearheaded by the firm Robbins Geller Rudman & Dowd LLP. They've sent out a call to arms for investors who suffered significant losses from February...

Continue Reading
Qingdao's Food Trade Triumph at SIAL Paris Booms

Updated Category News Views 3

Qingdao Impresses in the Global Food Arena Well, 2026 is serving up something special from Qingdao. During SIAL Paris, everyone's talking about how Qingdao’s food companies smashed expectations with 82 million yuan in intended orders. You’ve got CCPIT Qingdao pulling the strings, setting up an exhibition platform that was nothing short of top-tier. Staging a Show at...

Continue Reading
Electrolux Trends: Q3 '26 Shows Resilience Amid Challenges

Updated Category News Views 3

Electrolux's Strategic Moves In A Tough Market Electrolux's Q3 2026 paints a gritty picture—yet there's a pulse of resilience underneath the numbers. Net sales bumped up to SEK 33,919m due to a 3.5% organic growth, showing the company's ability to swim through choppy waters. But let's not brush aside the sharp rocks they’re dodging: soaring raw materials and logistics...

Continue Reading
TORL Bio's Ixo-V Drug Shows Promise in Combatting GCT

Updated Category News Views 2

A Beacon of Hope in Germ Cell Tumor Treatment There's something brewing in the oncology world that's worth a nod. TORL BioTherapeutics has rolled out some interesting preliminary data for their hopeful cancer buster, ixotatug vedotin, or Ixo-V. This study is part of a wider effort to take a swing at recurrent germ cell tumors (GCTs) with some tough results already making...

Continue Reading
Innventure Faces Chaotic Legal Storm Over DarkNX Scandal

Updated Category News Views 1

Innventure's DarkNX Project: From Boon to Bane The stock market is no stranger to seismic shifts, but Innventure, Inc.'s recent plunge is a testament to the catastrophic impact missteps can unleash. This whole DarkNX debacle feels more like a meticulous car wreck than a business evolution. Unpacking the Allegations Sitting comfortably under the NASDAQ:INV ticker,...

Continue Reading
Lowcountry Kids to Get Free Helmets at Safety Events

Updated Category News Views 1

Helmets for Kids Initiative Gets Rolling Now, here's a story that's more about community care than cash flow, but hey, sometimes even a grizzled trader like me can nod in appreciation. Christmas Injury Lawyers are putting their money where their mouth is, with the Helmets for Kids initiative staged at two key events in the Lowcountry area. Yep, that's right—the legal...

Continue Reading
ImmunoForge Sets Sights on BIO-Europe 2026 for New Deals

Updated Category News Views 3

Making Waves with Cutting-Edge Drug Platforms Ah, how time flies in the biotech universe. Here we are, with ImmunoForge prepping to flaunt its high-tech gear at the big show in Cologne: BIO-Europe 2026. The company's aiming to gauge attention with its flashy ELP and LMT platforms, primed and ready for strategic partnerships. ELP: Revolutionizing Drug Delivery You've got...

Continue Reading
Greenberg Traurig Eyes Accolades in Middle East Awards

Updated Category News Views 3

Greenberg Traurig Aims for Middle Eastern Legal Dominance Ah, the legal world, where firms jostle like bulls in a market for the prestige of an award—it's not just about the courtroom victories, but also about snatching the right titles at glossy ceremonies. On the docket this time: Greenberg Traurig has its sights set on several prime accolades at the Law Middle East...

Continue Reading
California Contractors Honored for Safety Commitment

Updated Category News Views 9

Commitment to Safety in the Construction Industry When it comes to construction, safety isn’t an afterthought—it’s woven into the very fabric of every project. The 39th Annual Construction Safety Excellence Awards by the Associated General Contractors of California (AGC of California) pits a spotlight on those embodying this ethos. Industry Leaders in Safety Held on...

Continue Reading
Dimethylaminopropylamine Market Eyes $732M by 2035

Updated Category News Views 0

Surfactants and Epoxy Fuel Dimethylaminopropylamine Demand Hot off the presses, folks! Dimethylaminopropylamine, or DMAPA if you're into acronyms, is gearing up for a steady climb to a $731.9 million market value by the year 2035. That's quite the leap from the $452.6 million we saw back in 2025. According to Credence Research's latest estimates, this amine is hitching...

Continue Reading

Top 5 Most Recently Viewed Articles

RPA Market Set to Surge with Digital Transformation Support

Updated Category News Views 218

Understanding the Growth of the Robotic Process Automation Market The Robotic Process Automation (RPA) market is experiencing remarkable growth, with forecasts indicating an increase from USD 2.8 billion in 2023 to a staggering USD 38.4 billion by 2032. This impressive growth, at a compound annual growth rate (CAGR) of 33.8% from 2024 to 2032, reflects the growing...

Continue Reading
Unlocking Hidden Gems: Two Undervalued China Stocks to Buy

Updated Category News Views 246

Discovering Hidden Opportunities in China's Stock Market As the Chinese stock market experiences a renewed rally, discerning investors are on the lookout for undervalued companies with promising growth prospects. In a landscape dominated by major players like Alibaba and Tencent, two lesser-known stocks are gaining attention: Futu Holdings (NASDAQ: FUTU) and Atour...

Continue Reading
Exploring the Rise of Medical Spas: A Booming Industry

Updated Category News Views 186

Introduction to the Medical Spa Industry The medical spa industry is experiencing an exciting evolution, reflecting a shift in consumer preferences towards services that combine traditional spa ambiance with the expertise of medical professionals. With an increasing focus on aesthetic wellness and anti-aging solutions, we are witnessing an impressive market growth...

Continue Reading
Coherent Corp. Launches Chameleon Discovery LX Laser for Researchers

Updated Category News Views 189

Coherent Corp. Launches an Innovative Femtosecond Laser Coherent Corp. (NYSE: COHR), a renowned leader in the laser and photonics industry, has unveiled the Chameleon Discovery LX, an exciting new addition to its esteemed Chameleon Discovery product line. This revolutionary femtosecond laser is specifically designed for researchers engaged in nonlinear microscopy and...

Continue Reading
Neuronetics Shows Strong Revenue Growth Amid CEO Transition

Updated Category News Views 134

Neuronetics Reports Impressive Q3 2025 Results Neuronetics, Inc., a leader in neurohealth therapies, has shared substantial financial achievements for the third quarter of 2025. The company reported total revenues of $37.3 million, marking an significant adjusted pro forma growth of 11% compared to the same quarter in the previous year. This success can largely be...

Continue Reading